Medpace Holdings Inc. (MEDP)
MEDP trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1668397/000166839726000006/0001668397-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MEDP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001668397 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.5B |
| Net income | $451.1M |
| Operating income | $534.9M |
| Net margin | 17.8% |
| Operating margin | 21.1% |
| Revenue growth | +20.0% |
| Cash | $497.0M |
| Total assets | $2.0B |
| P/E (computed) | 40.2× |
| P/S (computed) | 7.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-22 |
| Cash and burn | $705.3M cash; operating cash flow $180.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 27,971,686 (2026-10-16); 28,168,223 a year earlier; 30,683,436 three years earlier. | Cover page 2026-10-16 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Cincinnati, Ohio, United States | PCAOB Form AP 2026-02-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $436.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $716.0M | $137.5M | $216.6M | $705.3M | No debt tags | $2.8B | 10-Q 2026-10-22 |
| Q2 2026 2026-06-30 | $707.3M | $121.4M | $162.0M | $502.7M | No debt tags | $2.8B | 10-Q 2026-07-23 |
| Q1 2026 2026-03-31 | $706.6M | $123.9M | $151.8M | $652.7M | No debt tags | $2.7B | 10-Q 2026-04-23 |
| Q4 2025 2025-12-31 | $708.5M | $135.1M | $192.7M | $497.0M | No debt tags | $2.5B | 10-K 2026-02-10 |
| Q3 2025 2025-09-30 | $659.9M | $111.1M | $246.2M | $285.4M | No debt tags | $2.4B | 10-Q 2026-10-22 |
| Q2 2025 2025-06-30 | $603.3M | $90.3M | $148.5M | $46.3M | No debt tags | $2.2B | 10-Q 2026-07-23 |
| Q1 2025 2025-03-31 | $558.6M | $114.6M | $125.8M | $441.4M | No debt tags | $2.2B | 10-Q 2026-04-23 |
| Q4 2024 2024-12-31 | $536.6M | $117.0M | $190.7M | $669.4M | No debt tags | $2.1B | 10-K 2026-02-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-02-14 |
| Latest annual report | 10-K | 2026-02-10 |
| Latest quarterly / interim | 10-Q | 2026-10-22 |
| Latest current report | 8-K | 2026-10-21 |
| Latest proxy | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 932 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | +7.2% |
| 3 months | +12.4% |
| Year to date | +16.4% |
| 1 year | +10.6% |
| From 52-week high | -5.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
| IQV | IQVIA Holdings Inc. | $264.73 | -0.15% | $43.6B |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier